Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials

被引：0
|
作者：
Mohamed, Mohamed-Eslam [1 ]
Zeng, Jiewei [2 ]
Song, In-Ho [2 ]
Othman, Ahmed A. [2 ]
机构：
[1] AbbVie, Clin Pharmacol & Pharmacometr, N Chicago, IL USA
[2] AbbVie Inc, N Chicago, IL USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1629
引用
收藏
页数：2
相关论文
共 25 条
  • [1] ABT-494 PHARMACOKINETICS FOLLOWING ADMINISTRATION OF THE ONCE-DAILY EXTENDED-RELEASE TABLET FORMULATION BEING UTILIZED IN THE ONGOING RHEUMATOID ARTHRITIS PHASE 3 TRIALS
    Mohamed, M. -E. F.
    Zeng, J.
    Song, I. -H.
    Othman, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 268 - 269
  • [2] Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
    Mohamed, Mohamed-Eslam F.
    Zeng, Jiewei
    Marroum, Patrick J.
    Song, In-Ho
    Othman, Ahmed A.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (02): : 208 - 216
  • [3] ABT-494 HAS NO EFFECT ON THE QT INTERVAL AT THE DOSES BEING EVALUATED IN RHEUMATOID ARTHRITIS PHASE 3 TRIALS
    Mohamed, M-E. F.
    Zeng, J.
    Jiang, P.
    Hosmane, B.
    Othman, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1201 - 1201
  • [4] POPULATION PHARMACOKINETICS OF ABT-494 IN HEALTHY SUBJECTS AND IN SUBJECTS WITH RHEUMATOID ARTHRITIS: COMBINED ANALYSIS OF PHASE I AND II TRIALS
    Kluender, B.
    Mohamed, M. -E. F.
    Othman, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S79 - S79
  • [5] Pharmacokinetics of a Once-Daily Extended-Release Formulation of Pramipexole in Healthy Male Volunteers: Three Studies
    Jenner, Peter
    Koenen-Bergmann, Michael
    Schepers, Cornelia
    Haertter, Sebastian
    CLINICAL THERAPEUTICS, 2009, 31 (11) : 2698 - 2711
  • [6] Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation
    Huang, YB
    Tsai, YH
    Yang, WC
    Chang, JS
    Wu, PC
    Takayama, K
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (03) : 607 - 614
  • [7] Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food
    Lamba, Manisha
    Wang, Rong
    Fletcher, Tracey
    Alvey, Christine
    Kushner, Joseph
    Stock, Thomas C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (11): : 1362 - 1371
  • [8] Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women
    Fourcroy, JL
    Berner, B
    Chiang, YK
    Cramer, M
    Rowe, L
    Shore, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) : 4137 - 4143
  • [9] Comparative Pharmacokinetics of a Once-Daily Tramadol Extended-Release Tablet and an Immediate-Release Reference Product Following Single-Dose and Multiple-Dose Administration
    Karhu, David
    Fradette, Caroline
    Potgieter, Maria Alida
    Ferreira, Maria M.
    Terblanche, Johann
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (05): : 544 - 553
  • [10] Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study)
    Tompson, Debra J.
    Ali, Imran
    Oliver-Willwong, Ruth
    Job, Sarah
    Zhu, Li
    Lemme, Francesca
    Hammer, Anne E.
    Vuong, Alain
    Messenheimer, John A.
    EPILEPSIA, 2008, 49 (03) : 410 - 417
123